Boardroom Alpha
Boardroom Alpha
MDGL · Additional Proxy Materials (DEFA14A) · Filed April 28, 2026

Madrigal Pharmaceuticals Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 28, 2026
Ticker
MDGL
Accession
0001104659-26-050349
Boardroom Alpha · Filing insights

Madrigal's board urges voting FOR Proposals 1–5 at the June 17, 2026 meeting, including director re-elections and stock plans.

About Madrigal Pharmaceuticals Inc
Market cap
$10.4B
1Y TSR
+80.2%
3Y TSR
+26.9%
Board grade
B-
Sector
Healthcare
CEO
William John Sibold
Last annual meeting: Jun 17, 2026 · View full Madrigal Pharmaceuticals Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

 

Filed by the Registrant x        Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

 

¨ Preliminary Proxy Statement
   
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
¨ Definitive Proxy Statement
   
x Definitive Additional Materials
   
¨ Soliciting Material under §240.14a-12

 

MADRIGAL PHARMACEUTICALS, INC.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):
   
x No fee required.
   
¨ Fee paid previously with preliminary materials.
   
¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

 

GRAPHIC

Your control number Your vote matters! Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 17, 2026 For Stockholders of record as of April 23, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/MDGL Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved Madrigal Pharmaceuticals, Inc. Annual Meeting of Stockholders Wednesday, June 17, 2026 8:00 AM, Eastern Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/MDGL to register to attend the Annual Meeting For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting, go to www.proxydocs.com/MDGL To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 5, 2026. styleINA P.O. BOX 8016, CARY, NC 27512-9903 SEE REVERSE FOR FULL AGENDA

GRAPHIC

PROPOSAL 1. Re-election of Class I directors: 1.01 Julian Baker 1.02 Daniel Brennan 1.03 James Daly 2. Advisory vote to approve executive compensation 3. To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 4. Approval of Madrigal Pharmaceuticals, Inc. 2026 Stock Plan 5. Approval of Madrigal Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan 6. Such other business as may properly come before the meeting or any adjournment orpostponement thereof. THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2, 3, 4 AND 5 Madrigal Pharmaceuticals, Inc. Annual Meeting of Stockholders

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Madrigal Pharmaceuticals Inc (MDGL)

Reference

Frequently asked questions

When did Madrigal Pharmaceuticals Inc file this DEFA14A?
Madrigal Pharmaceuticals Inc (MDGL) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 28, 2026. The accession number assigned by EDGAR is 0001104659-26-050349.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Madrigal's board urges voting FOR Proposals 1–5 at the June 17, 2026 meeting, including director re-elections and stock plans. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Madrigal Pharmaceuticals Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Madrigal Pharmaceuticals Inc has filed under CIK 1157601, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer